Ancep Secures $8.5Mn Funding Led by Creandum for AI Insurance Platform

Several angel investors also took part, including former Aon CFO Christa Davies and professionals from OpenAI, Anthropic and Google DeepMind.

Gagan Khurana, co-founder and CEO of Ancep, said, "What we sell is net new revenue. Plenty of people are betting brokers get disintermediated. We think the opposite: brokers have huge leverage, and no chatbot is going to replace it. So we are not building around them, we are building for them, and we are starting with the twenty largest in the world."

Ancep develops AI agents that help commercial insurance brokers handle routine work. The technology automates tasks involved in arranging insurance policies, helping brokers manage more clients and business opportunities without adding to their administrative workload.

Commercial insurance brokers are facing pressure as insurance rates decline. Smaller policies can also require almost as much paperwork as larger ones, even though they generate lower commissions. Because of this, brokers may give less attention to smaller policies or turn them down, missing potential business opportunities.

Ancep aims to solve this problem by automating the paperwork and other routine steps involved in arranging insurance. Its AI agents review client submissions, prepare insurance documents and contact insurers to collect policy terms.

The platform works with brokers' existing software and systems. This includes policy management platforms, online insurance portals and customer relationship management (CRM) tools. It can contact insurers through email, online portals and APIs.

Ancep's technology is designed to support brokers, not replace them. Brokers remain responsible for approving and binding insurance policies, while their teams review the work completed by AI agents. The company also keeps each brokerage's client data separate and does not share or use it to train systems across different brokerages without permission.

Read Also- UK Biotech Startup Neobe Therapeutics Raises €6.1Mn to Develop Bacteria-Based Cancer Treatments